Evidence map›Paper›PMID 31694946›Full record

ArticleJournal of virology2020

VAMP8 Contributes to the TRIM6-Mediated Type I Interferon Antiviral Response during West Nile Virus Infection.

Sarah van Tol, Colm Atkins, Preeti Bharaj, Kendra N Johnson, Adam Hage, Alexander N Freiberg, Ricardo Rajsbaum

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. VAMP8 function reveals tight linkage between endocytic recycling and endocytosis.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. The Molecular and Function Characterization of Porcine MID2.Animals : an open access journal from MDPI · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sarah van Tol *Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Colm Atkins *Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0003-4110-161X
Preeti BharajDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Kendra N JohnsonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Adam HageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Alexander N FreibergDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA anfreibe@utmb.edu rirajsba@utmb.edu.
Ricardo RajsbaumDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA anfreibe@utmb.edu rirajsba@utmb.edu.
The University of Texas Medical Branch at Galveston · US

Funding

West African Center for Emerging Infectious DiseasesU01AI151801 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Robert W Cross, Scott C Weaver · 2020 to 2026
$10.1M
Regulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1M
EMERGING AND TROPICAL INFECTIOUS DISEASEST32AI007526 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SOONG, LYNN · 1997 to 2025
$3.1M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
Bioavailable proteasome inhibitors as broad-spectrum antiviralsR33AI102267 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI FREIBERG, ALEXANDER NICLAS · 2014 to 2016
$1.2M
The role of the host ubiquitin system in Zika virus replicationR21AI132479 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RAJSBAUM, RICARDO · 2017 to 2018
$426k
Unanchored Polyubiquitin Chains and Innate Immunity to Influenza VirusR21AI126012 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RAJSBAUM, RICARDO · 2017 to 2018
$426k
NIAID NIH HHS R01 AI134907NIAID NIH HHS R21 AI126012NIAID NIH HHS R21 AI132479NIAID NIH HHS R33 AI102267NIAID NIH HHS T32 AI007526NIAID NIH HHS T32 AI060549NIAID NIH HHS U01 AI151801
6 · The paper itself

Abstract

Several members of the tripartite motif (TRIM) family of E3 ubiquitin ligases regulate immune pathways, including the antiviral type I interferon (IFN-I) system. Previously, we demonstrated that TRIM6 is involved in IFN-I induction and signaling. In the absence of TRIM6, optimal IFN-I signaling is reduced, allowing increased replication of interferon-sensitive viruses. Despite having evolved numerous mechanisms to restrict the vertebrate host's IFN-I response, West Nile virus (WNV) replication is sensitive to pretreatment with IFN-I. However, the regulators and products of the IFN-I pathway that are important in regulating WNV replication are incompletely defined. Consistent with WNV's sensitivity to IFN-I, we found that in TRIM6 knockout (TRIM6-KO) A549 cells, WNV replication is significantly increased and IFN-I induction and signaling are impaired compared to wild-type (wt) cells. IFN-β pretreatment was more effective in protecting against subsequent WNV infection in wt cells than TRIM6-KO, indicating that TRIM6 contributes to the establishment of an IFN-induced antiviral response against WNV. Using next-generation sequencing, we identified VAMP8 as a potential factor involved in this TRIM6-mediated antiviral response. VAMP8 knockdown resulted in reduced JAK1 and STAT1 phosphorylation and impaired induction of several interferon-stimulated genes (ISGs) following WNV infection or IFN-β treatment. Furthermore, VAMP8-mediated STAT1 phosphorylation required the presence of TRIM6. Therefore, the VAMP8 protein is a novel regulator of IFN-I signaling, and its expression and function are dependent on TRIM6 activity. Overall, these results provide evidence that TRIM6 contributes to the antiviral response against WNV and identify VAMP8 as a novel regulator of the IFN-I system.

Indexed as

Immunity, InnateA549 CellsGene DeletionHEK293 CellsHumansInterferon Type IJanus Kinase 1PhosphorylationR-SNARE ProteinsSTAT1 Transcription FactorTripartite Motif ProteinsUbiquitin-Protein LigasesVirus ReplicationWest Nile FeverWest Nile virusInterferon Type IJAK1 protein, humanJanus Kinase 1R-SNARE ProteinsSTAT1 protein, humanSTAT1 Transcription FactorTRIM6 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesVAMP8 protein, humanflavivirusimmunologyTRIM6type I interferon pathwayubiquitinVAMP8West Nile virus

Identifiers

PMID31694946
PMCPMC6955268
OpenAlexW2984948991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.